rhGM-CSF

PreclinicalSmall molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

rhGM-CSF is one of 7 small molecule programs targeting Oligometastatic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligometastaticUnknown status

OligometastaticPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Oligometastatic

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

1 2

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 3

Vepesid

AAvyxa

Phase 2

1 4

Lu-PSMA I&T

MMedical University of Vienna

Phase 2

1 5

Carboplatin/cisplatin

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

1 6

rhGM-CSF

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

1 7

Single Agent

SShandong Cancer Hospital and Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01341652·99 enrolled

Non-Small Cell Lung Cancer1 trial

Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer

Completed·PPeking University Cancer Hospital & Institute·Phase 2·NCT03113851·40 enrolled

Oral Mucositis1 trial

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis

Unknown status·WWei LUO·Phase 2·NCT01806272·160 enrolled

Stage IV NSCLC1 trial

A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Withdrawn·WWuhan University·Phase 2·NCT02623595

Stage III Colon Cancer1 trial

RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 2·NCT02466906·60 enrolled

4 more indications

Oligometastatic1 trial

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

Unknown status·SShandong Cancer Hospital and Institute·N/A·NCT03489616·45 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn

Completed· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 4·NCT01785784·2,510 enrolled

Melanoma1 trial

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Unknown status·XXiangya Hospital of Central South University·Phase 1·NCT04072900·30 enrolled

Unspecified1 trial

Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT01983657·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for rhGM-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhGM-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhGM-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

rhGM-CSF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Oral Mucositis1 trial

Stage IV NSCLC1 trial

Stage III Colon Cancer1 trial

Oligometastatic1 trial

Efficacy and Safety1 trial

Melanoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News